| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 2,269 | 2,291 | 2,286 | 2,300 | 2,310 | 2,232 | 2,360 | 2,266 | 2,479 | 2,127 | 3,165 | 3,206 | 3,197 | 2,870 | 2,875 | 3,547 | 3,658 | 3,429 | 3,271 | 3,555 | 3,672 | 3,462 | 3,663 | 3,645 | 3,551 | 3,971 | 6,106 | 3,590 | 3,821 | 3,989 | 3,993 | 4,199 | 4,890 | 5,089 | 4,313 | 4,403 | 5,526 | 6,110 | 5,182 | 5,181 | 6,371 | 6,622 | 6,147 |
| Expenses | 1,792 | 1,807 | 1,740 | 1,768 | 1,784 | 1,763 | 1,841 | 1,907 | 2,004 | 1,909 | 2,365 | 2,404 | 2,399 | 2,249 | 2,273 | 2,738 | 2,932 | 2,864 | 3,009 | 2,947 | 3,013 | 2,724 | 2,977 | 2,867 | 2,916 | 3,092 | 2,860 | 2,895 | 3,103 | 3,251 | 3,319 | 3,301 | 4,359 | 3,650 | 3,224 | 3,403 | 3,903 | 4,124 | 3,776 | 3,882 | 4,622 | 4,485 | 4,142 |
| EBITDA | 477 | 484 | 546 | 532 | 526 | 468 | 519 | 359 | 476 | 218 | 800 | 802 | 798 | 621 | 601 | 809 | 726 | 565 | 262 | 608 | 658 | 738 | 686 | 779 | 635 | 879 | 3,246 | 695 | 718 | 738 | 673 | 898 | 532 | 1,439 | 1,089 | 1,000 | 1,623 | 1,986 | 1,407 | 1,299 | 1,749 | 2,137 | 2,005 |
| Operating Profit % | 20 % | 20 % | 23 % | 22 % | 21 % | 20 % | 21 % | 15 % | 17 % | 9 % | 25 % | 24 % | 24 % | 19 % | 20 % | 22 % | 19 % | 16 % | 7 % | 17 % | 17 % | 20 % | 17 % | 20 % | 19 % | 21 % | 22 % | 18 % | 17 % | 17 % | 16 % | 21 % | 10 % | 28 % | 24 % | 22 % | 27 % | 32 % | 26 % | 24 % | 27 % | 31 % | 31 % |
| Depreciation | 76 | 69 | 73 | 74 | 76 | 84 | 86 | 90 | 114 | 122 | 126 | 147 | 144 | 142 | 148 | 154 | 156 | 172 | 172 | 174 | 179 | 173 | 175 | 176 | 175 | 183 | 177 | 177 | 185 | 181 | 182 | 182 | 179 | 180 | 184 | 195 | 205 | 215 | 234 | 229 | 238 | 238 | 302 |
| Interest | 16 | 12 | 13 | 12 | 16 | 14 | 15 | 7 | 10 | 22 | 41 | 13 | 15 | 35 | 36 | 46 | 77 | 89 | 90 | 81 | 83 | 68 | 45 | 27 | 23 | 27 | 30 | 31 | 39 | 34 | 35 | 33 | 28 | 18 | 9 | 20 | 35 | 32 | 25 | 32 | 77 | 85 | 101 |
| Profit Before Tax | 426 | 519 | 545 | 537 | 498 | 441 | 435 | 324 | 412 | 154 | 712 | 722 | 724 | 570 | 535 | 672 | 606 | 394 | 122 | 457 | 522 | 588 | 524 | 617 | 526 | 777 | 3,135 | 598 | 558 | 673 | 648 | 781 | 484 | 1,328 | 1,006 | 947 | 1,550 | 1,900 | 1,271 | 1,184 | 1,672 | 1,921 | 1,687 |
| Tax | 69 | 51 | 60 | 97 | -74 | 36 | 46 | -6 | 20 | 9 | 200 | 168 | 125 | 102 | 107 | 150 | 124 | 69 | 28 | 86 | 108 | 102 | 89 | 89 | -210 | 135 | 123 | 87 | 105 | 96 | 122 | 149 | 125 | 195 | 203 | 157 | 304 | 417 | 351 | 158 | 428 | 400 | 449 |
| Net Profit | 357 | 468 | 485 | 440 | 572 | 405 | 389 | 331 | 393 | 145 | 513 | 553 | 599 | 467 | 428 | 522 | 482 | 325 | 94 | 371 | 414 | 487 | 435 | 528 | 735 | 643 | 3,012 | 511 | 453 | 576 | 526 | 631 | 358 | 1,134 | 803 | 790 | 1,246 | 1,483 | 920 | 1,026 | 1,244 | 1,521 | 1,239 |
| EPS in ₹ | 17.11 | 22.47 | 6.46 | 4.21 | 5.59 | 3.89 | 3.71 | 3.16 | 3.77 | 1.35 | 4.92 | 5.31 | 5.77 | 4.50 | 4.08 | 4.99 | 4.40 | 2.97 | 1.05 | 3.65 | 3.83 | 4.43 | 4.62 | 5.15 | 6.64 | 5.74 | 29.32 | 4.89 | 3.88 | 5.06 | 5.15 | 6.15 | 2.93 | 10.74 | 7.91 | 7.80 | 11.69 | 14.11 | 9.06 | 10.17 | 11.64 | 14.58 | 12.51 |
Zydus Life Science
Zydus Life Science
882.00
-3.30
(-0.37%)
Market Cap
88,749.84 Cr
PE Ratio
17.70
Volume
4,60,331.00
Day High - Low
897.15 - 880.00
52W High-Low
1,059.05 - 795.00
Key Fundamentals
Market Cap
88,749.84 Cr
EPS
44.97
PE Ratio
17.70
PB Ratio
3.52
Book Value
251.45
EBITDA
7,328.00
Dividend Yield
1.24 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
17.51
Debt to Equity
0.09
Analyst Rating and Forecast
- By Refinitiv from28 analysts
Actual
Company News
View All News
Zydus Lifesciences' Unit-2 manufacturing plant at Ankleswar completed USFDA inspection from January 19-23, 2026, receiving 3 observations with no data integrity issues reported.
S&P Global has revised Zydus Lifesciences' Corporate Sustainability Assessment ESG Score from 83/100 to 84/100 for 2025, marking an improvement in the company's sustainability performance.
Zydus Lifesciences successfully completed acquisition of Agenus Inc.'s biologics facilities and equity stake, establishing Zylidac Bio LLC for US CDMO operations with regulatory approvals including CFIUS clearance.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,631.90 | #1 3,91,547.47 | 37.40 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 32.48 | |
6,011.50 | 1,59,586.44 | 64.87 | 9,712.00 | 18.67 | 2,191 | 35.10 | 31.96 | |
3,932.20 | 1,33,083.52 | 63.64 | 11,539.40 | 6.99 | 1,911 | 30.46 | 51.26 | |
1,315.00 | 1,06,221.99 | 20.39 | 28,409.50 | 7.12 | 5,291 | 3.71 | 16.66 | |
1,235.60 | 1,03,126.93 | 18.39 | 33,741.20 | 16.73 | 5,725 | -15.28 | 53.53 | |
2,137.20 | 97,627.04 | 22.75 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 49.85 | |
882.00 | #7 88,749.84 | #1 17.70 | #5 23,511.00 | #3 18.55 | #4 4,615 | #3 34.60 | 39.82 | |
2,107.60 | 87,002.80 | 49.98 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 41.23 | |
5,750.50 | 68,755.85 | 28.60 | 13,458.30 | 3.70 | 2,216 | 10.98 | 54.24 | |
1,132.50 | 65,775.78 | 19.45 | 32,345.60 | 9.43 | 3,484 | 3.81 | 37.32 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
18.55 %
Net Income Growth
20.45 %
Cash Flow Change
112.02 %
ROE
0.98 %
ROCE
7.64 %
EBITDA Margin (Avg.)
9.06 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 9,047 | 10,551 | 15,221 | 18,065 | 23,483 | 23,687 | 23,885 | 27,795 | 25,756 | 29,281 | 37,202 |
| Fixed Assets | 3,352 | 3,748 | 5,755 | 6,483 | 12,164 | 12,231 | 12,133 | 12,189 | 11,521 | 12,369 | 13,134 |
| Current Assets | 4,227 | 4,280 | 6,022 | 8,230 | 8,498 | 8,715 | 8,716 | 12,095 | 10,008 | 11,420 | 17,046 |
| Capital Work in Progress | 798 | 951 | 1,543 | 1,527 | 837 | 742 | 783 | 726 | 1,201 | 2,423 | 2,692 |
| Investments | 121 | 416 | 435 | 746 | 674 | 765 | 830 | 3,288 | 1,547 | 1,221 | 6,408 |
| Other Assets | 4,776 | 5,436 | 7,488 | 9,310 | 9,809 | 9,950 | 10,139 | 11,593 | 11,488 | 13,269 | 14,968 |
| Total Liabilities | 9,047 | 10,551 | 15,221 | 18,065 | 23,483 | 23,687 | 23,885 | 27,795 | 25,756 | 29,281 | 37,202 |
| Current Liabilities | 3,285 | 3,461 | 5,306 | 6,083 | 7,343 | 8,269 | 7,861 | 7,827 | 5,527 | 5,340 | 9,042 |
| Non Current Liabilities | 1,342 | 1,255 | 2,799 | 3,047 | 4,461 | 3,707 | 1,094 | 915 | 541 | 1,840 | 1,802 |
| Total Equity | 4,421 | 5,835 | 7,116 | 8,936 | 11,679 | 11,710 | 14,930 | 19,054 | 19,688 | 22,102 | 26,358 |
| Reserve & Surplus | 4,149 | 5,597 | 6,858 | 8,642 | 10,284 | 10,273 | 12,890 | 16,897 | 17,415 | 19,729 | 23,853 |
| Share Capital | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 101 | 101 | 101 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 178 | 99 | 756 | -3 | -811 | 399 | -91 | 219 | -170 | -75 | 414 |
| Investing Activities | -465 | -860 | -2,872 | -974 | -3,977 | -1,004 | -837 | -1,018 | 1,542 | -1,492 | -8,377 |
| Operating Activities | 994 | 1,894 | 1,312 | 919 | 1,282 | 2,932 | 3,294 | 2,105 | 2,689 | 3,196 | 6,777 |
| Financing Activities | -351 | -935 | 2,316 | 52 | 1,885 | -1,528 | -2,548 | -868 | -4,400 | -1,779 | 2,014 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
| Promoter | 74.88 % | 74.88 % | 74.88 % | 74.88 % | 74.88 % | 74.88 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.99 % | 74.99 % | 74.99 % | 75.00 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 5.72 % | 5.59 % | 7.52 % | 7.53 % | 7.32 % | 7.13 % | 7.34 % | 7.06 % |
| DIIs | 11.11 % | 10.43 % | 11.22 % | 11.78 % | 12.78 % | 11.92 % | 12.94 % | 13.69 % | 13.60 % | 13.23 % | 13.09 % | 12.79 % | 12.63 % | 12.64 % | 10.65 % | 10.65 % | 11.01 % | 11.13 % | 10.86 % | 11.09 % |
| Government | 0.19 % | 0.07 % | 0.07 % | 0.07 % | 0.08 % | 0.08 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 6.16 % | 7.31 % | 7.38 % | 7.40 % | 7.81 % | 8.02 % | 7.60 % | 7.04 % | 6.42 % | 5.97 % | 5.67 % | 5.60 % | 5.29 % | 5.37 % | 5.48 % | 5.47 % | 5.41 % | 5.46 % | 5.49 % | 5.54 % |
| Others | 7.66 % | 7.32 % | 6.44 % | 5.87 % | 4.46 % | 5.11 % | 4.48 % | 4.29 % | 5.00 % | 5.82 % | 6.26 % | 6.63 % | 1.38 % | 1.43 % | 1.37 % | 1.36 % | 1.28 % | 1.28 % | 1.32 % | 1.31 % |
| No of Share Holders | 0 | 2,23,384 | 3,31,155 | 3,51,595 | 3,70,931 | 4,08,017 | 4,55,624 | 4,08,231 | 3,70,396 | 3,11,764 | 2,97,953 | 3,06,495 | 2,94,324 | 3,36,309 | 3,70,863 | 3,65,356 | 3,71,619 | 3,86,127 | 3,96,105 | 4,03,266 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 3.2 | 3.5 | 3.5 | 3.5 | 3.5 | 2.5 | 6 | 3 | 11 | 0.00 |
| Dividend Yield (%) | 0.85 | 1.01 | 1.31 | 0.79 | 1 | 0.51 | 0.6 | 0.34 | 1.25 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 30 Jul 2021 |  Dividend | ₹ 3.50 /share | 28 Jul 2021 | 628.10 | 571.90 |
| 29 Jul 2022 | Dividend | ₹ 2.50 /share | 28 Jul 2022 | 338.75 | 349.60 |
| 28 Jul 2023 | Dividend | ₹ 6.00 /share | 28 Jul 2023 | 518.80 | 649.50 |
| 29 Feb 2024 |  Buyback | 1005 | 23 Feb 2024 | 953.75 | 932.80 |
| 26 Jul 2024 | Dividend | ₹ 3.00 /share | 26 Jul 2024 | 1,009.00 | 1,205.80 |
| 09 Aug 2024 |  Annual General Meeting | NA | 09 Aug 2024 | 1,009.00 | 1,279.40 |
| 12 Nov 2024 |  Quarterly Result Announcement | NA | 12 Nov 2024 | 1,002.20 | 968.55 |
| 05 Feb 2025 | Quarterly Result Announcement | NA | 05 Feb 2025 | 995.50 | 974.00 |
| 20 May 2025 | Quarterly Result Announcement | NA | 20 May 2025 | 873.70 | 911.40 |
| 25 Jul 2025 | Dividend | ₹ 11.00 /share | 25 Jul 2025 | 902.70 | 971.05 |
| 12 Aug 2025 | Quarterly Result Announcement | NA | 12 Aug 2025 | 969.80 | 955.50 |
| 12 Aug 2025 | Annual General Meeting | NA | 12 Aug 2025 | 911.40 | 955.50 |
| 06 Nov 2025 | Quarterly Result Announcement | NA | 06 Nov 2025 | 1,001.35 | 971.70 |
Announcements
Announcement under Regulation 30 (LODR)-Press Release / Media Release
1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release3 days ago
3 days agoRevision In ESG Rating5 days ago
5 days agoUpdate7 days ago
7 days agoClosing Of Acquisition9 days ago
9 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release9 days ago
9 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 13, 2026
Jan 13, 2026UpdateJan 10, 2026
Jan 10, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 07, 2026
Jan 07, 2026UpdatesJan 02, 2026
Jan 02, 2026Receipt Of Demand Order-In-Original From Assistant Commissioner Of State Tax GujaratDec 30, 2025
Dec 30, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationDec 27, 2025
Dec 27, 2025Intimation Of ESG RatingDec 26, 2025
Dec 26, 2025Closure of Trading WindowDec 26, 2025
Dec 26, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationDec 26, 2025
Dec 26, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionDec 24, 2025
Dec 24, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 23, 2025
Dec 23, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 19, 2025
Dec 19, 2025Intimation Of ESG RatingDec 16, 2025
Dec 16, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 15, 2025
Dec 15, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotDec 12, 2025
Dec 12, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportDec 12, 2025
Dec 12, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotDec 12, 2025
Dec 12, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 10, 2025
Dec 10, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 09, 2025
Dec 09, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseDec 04, 2025
Dec 04, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 27, 2025
Nov 27, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 26, 2025
Nov 26, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 25, 2025
Nov 25, 2025Announcement under Regulation 30 (LODR)-Investor PresentationNov 25, 2025
Nov 25, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 22, 2025
Nov 22, 2025General UpdateNov 19, 2025
Nov 19, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 18, 2025
Nov 18, 2025Disclosure Under SEBI (Prohibition Of Insider Trading) Regulations 2015Nov 17, 2025
Nov 17, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 14, 2025
Nov 14, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 14, 2025
Nov 14, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 13, 2025
Nov 13, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 13, 2025
Nov 13, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 13, 2025
Nov 13, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 13, 2025
Nov 13, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 13, 2025
Nov 13, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 12, 2025
Nov 12, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotNov 11, 2025
Nov 11, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 11, 2025
Nov 11, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 07, 2025
Nov 07, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 07, 2025
Nov 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 06, 2025
Nov 06, 2025Announcement under Regulation 30 (LODR)-Investor PresentationNov 06, 2025
Nov 06, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 06, 2025
Nov 06, 2025Announcement under Regulation 30 (LODR)-Raising of FundsNov 06, 2025
Nov 06, 2025Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 39.82
ATR(14)
Volatile 16.93
STOCH(9,6)
Neutral 31.42
STOCH RSI(14)
Neutral 39.84
MACD(12,26)
Bearish -1.34
ADX(14)
Weak Trend 18.96
UO(9)
Bearish 41.56
ROC(12)
Downtrend And Accelerating -5.27
WillR(14)
Neutral -69.37
About Zydus Life Science
Zydus Lifesciences Limited is an Indian global life sciences company that discovers, develops, manufactures, and markets healthcare therapies. Its product portfolio includes active pharmaceutical ingredients, human formulations, animal health products, and wellness products. The company operates in pharmaceuticals, covering human and veterinary formulations, bulk drugs, diagnostics, herbal products, skin care,...more
Listing Date
27 Apr, 2000(25 Years,
29 days)
Website
Chairperson NamePankaj R Patel
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
